Table 3.4.
Iron chelators
| Agent | Route half-life | Classificationa | Dose and regimen | Common or typical adverse effects |
|---|---|---|---|---|
| Deferoxamine | IV or SQ 8–10 min |
Hexadentate | 30–40 mg/kg/day over 8–12 h 5–7 day/week |
Anaphylaxis Local irritation Retinopathy Hearing loss Renal dysfunction Hepatic dysfunction |
| Deferasirox | Oral 12–18 h |
Tridentate | 20–40 mg/kg/day Once daily |
Diarrhea Rash Proteinuria Renal dysfunction Hepatic dysfunction− |
| Deferiprone | Oral 1.5–4 h |
Bidentate | 75–100 mg/kg/day 3 divided doses daily |
Arthralgia Arthropathy Agranulocytosis Renal dysfunction Hepatic dysfunction |
a
Indicates the number of coordination sites of the Fe atom that each molecule of the chelator can bind with; Fe has 6 coordination sites